Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech executive for guidance. But if the company thought those moves would be enough to placate angry activists, it was wrong. More: Allergan taps Celgene vet Hugin
read moreBayer and Johnson & Johnson inked a $775 million deal to wrap up about 25,000 Xarelto lawsuits that claim the anticoagulant caused severe and sometimes fatal episodes of bleeding. More: What's it cost to resolve 25,000 Xarelto lawsuits? For Bayer
read moreLast week, Bayer lost phase one of the first Roundup bellwether trial, which could set the tone for more than 11,200 others waiting in the wings. But to hear chief executive Werner Baumann tell it, the loss hasn’t shaken the
read moreWith the number of gene therapies under development growing, CDMOs are figuring out how to get a bigger piece of the market. Thermo Fisher Scientific decided to buy its way in, agreeing to pay $1.7 billion to get viral vector
read moreEli Lilly is under the gun for insulin price hikes, facing lawsuits, congressional scrutiny and general public outcry. But the drugmaker has repeatedly said it’s not profiting off those increases, and in its new annual report, it offers up some
read moreThe UK Biotech industry is showing a strong outlook at the start of 2019, despite the uncertainties of Brexit. More: UK Biotech still going strong at the start of 2019 Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals